Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 3 Interventional Results available

Clinical Trial Ceftriaxone in Subjects With ALS

NCT00349622
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
ceftriaxone, placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
50
States / cities
Phoenix, Arizona • Davis, California • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 2 Interventional

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

NCT00725803
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, GS-9450 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Anaheim, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion

NCT03274453
View directory record Official record
Conditions
Spinal Fusion
Interventions
Ketamine, Saline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Not applicable Interventional Results available

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645
View directory record Official record
Conditions
Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions
low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine
Other · Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 15, 2026, 3:41 AM EDT
Recruiting Phase 4 Interventional

Study of G-CSF for DOR in Patients Undergoing IVF

NCT07871825
View directory record Official record
Conditions
Diminished Ovarian Reserve, IVF, G-CSF, Granulocyte Colony Stimulating Factor
Interventions
Neupogen 300 μg subcutaneous injection, Subcutaneous injections of a saline solution
Drug · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
35 Years to 44 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

NCT00688376
View directory record Official record
Conditions
Attention Impairment
Interventions
Donepezil hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Stanford, California • Miami, Florida • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 15, 2026, 3:41 AM EDT
Recruiting Phase 2 Interventional

Convalescent Plasma as a Possible Treatment for COVID-19

NCT04442191
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma, Placebo
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Rest 2: A Study of Health and Wellness Products on Sleep and Health Outcomes

NCT05657808
View directory record Official record
Conditions
Sleep, Sleep Disturbance, Sleep Disorder
Interventions
Rest Study Active Product 1.1 Usage, Rest Study Active Product 1.2 Usage, Rest Study Active Product 2.1 Usage, Rest Study Active Product 2.2 Usage, Placebo Control Form 1, Placebo Control Form 2, Placebo Control Form 3, Rest Study Active Product 3.1 Usage, Placebo Control Form 4, Rest Study Active Product 4.1 Usage, Rest Study Active Product 4.2 Usage, Rest Study Active Product 4.3 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
4,152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

NCT00723489
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years to 43 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 15, 2026, 3:41 AM EDT
Terminated Phase 2 Interventional Results available

Simvastatin Augmentation of Lithium Treatment in Bipolar Depression

NCT01665950
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00264550
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab 100 mg, Golimumab 50 mg, Methotrexate, Placebo injection, Placebo capsules
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
13
States / cities
Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

NCT03259074
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
19
States / cities
Mesa, Arizona • Escondido, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 15, 2026, 3:41 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population

NCT06538584
View directory record Official record
Conditions
Enhanced Recovery After Surgery in a Pediatric Population
Interventions
Caffeine citrate 15mg/kg, 0.9% Sodium Citrate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
3 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Not applicable Interventional Results available

The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease

NCT02544984
View directory record Official record
Conditions
Chronic Lung Disease
Interventions
Azithromycin, placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Months to 6 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 15, 2026, 3:41 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

NCT07738614
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Eloralintide, Placebo, Acetaminophen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

NCT01569451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rituximab, Glatiramer Acetate, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Results available

IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty

NCT03020966
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Acetaminophen
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pentavalent DTaP-Hep B-IPV

NCT00133445
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions
DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 5 Days
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 15, 2026, 3:41 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19

NCT04771351
View directory record Official record
Conditions
Covid19
Interventions
COVI-AMG, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brandon, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 15, 2026, 3:41 AM EDT
Completed Phase 2 Interventional

Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

NCT03169231
View directory record Official record
Conditions
Aging Frailty
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
70 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Aventura, Florida • Coral Gables, Florida • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 15, 2026, 3:41 AM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 15, 2026, 3:41 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT07467993
View directory record Official record
Conditions
Schizophrenia
Interventions
GXV813, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Bentonville, Arkansas • Pico Rivera, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 3:41 AM EDT